Clinical Trials on Newborn Infant in Switzerland

Total 96 results

University of Lausanne Hospitals
Société des Produits Nestlé (SPN)

Completed

Monitoring of Postprandial Glycemic Variability in Healthy Young Infants (IGVM)

Glucose Intolerance | Infant Conditions

Switzerland
Sven Schulzke
Bern University of Applied Sciences

Completed

Maturational Changes in Newborn Infants

Immature Newborn | Abnormal Coordination

Switzerland
University Hospital, Clermont-Ferrand
Groupe Hospitalier Pitie-Salpetriere; University Hospital Schleswig-Holstein; Hospital Clínico Universitario de Valencia

Completed

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19) (ISCA)

Acute Respiratory Distress Syndrome | Sedation | Invasive Mechanical Ventilation | Critically Illness

United States, France, Spain, Germany, Switzerland
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Switzerland, Australia
St. Justine's Hospital

Completed

Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury (PALIVE1)

Acute Respiratory Distress Syndrome | Acute Lung Injury

France, Switzerland, Austria, United States, Spain, Canada, Belgium, Germany, Italy, Netherlands, Sweden, United Kingdom
Actelion

Terminated

Persistent Pulmonary Hypertension of the Newborn (FUTURE 4)

Persistent Pulmonary Hypertension of the Newborn

United States, Australia, Belgium, Czech Republic, France, Germany, Korea, Republic of, Poland, Russian Federation, Singapore, Switzerland, United Kingdom
University Medicine Greifswald

Recruiting

European Disease Registry on Retinopathy of Prematurity (ROP) (EU-ROP)

Retinopathy of Prematurity

Germany, Greece, Austria, Bulgaria, Estonia, France, Kosovo, Poland, Spain, Switzerland, Turkey, Ukraine
Wuerzburg University Hospital

Completed

Effects of a Partially Supervised Conditioning Program in CF (ACTIVATE-CF)

Cystic Fibrosis

United States, Austria, Canada, France, Germany, Netherlands, Switzerland, United Kingdom
Insel Gruppe AG, University Hospital Bern

Completed

Functional Residual Capacity Under Apnoeic Oxygenation With Different Flow Rates in Children (FUTURE)

Apnea | Anesthesia | Intubation Complication | Children, Only | Atelectasis | Ventilation Therapy; Complications | Apnea Infant

Switzerland
University of Basel
University of Pittsburgh; University Hospital Inselspital, Berne; University...

Completed

Pain Reactivity to Non-Pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit (PAMINA)

Preterm Infants

Switzerland
Hospices Civils de Lyon

Completed

Evaluation of a Peer Counseling Breastfeeding Support Program for Mother-preterm Infant Dyads (ALAIS)

Infant Premature

France, Switzerland, Belgium
Novartis Pharmaceuticals

Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Cystic Fibrosis

Spain, Germany, Switzerland, United Kingdom, Ireland
University of Zurich

Unknown

Executive Function in Preterm Born Children: An Integrative Approach From Genetics to Brain Function

Preterm Infants

Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Cystic Fibrosis

United Kingdom, France, Germany, Australia, Switzerland, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
University Hospital, Geneva

Completed

Milk-induced Gastrointestinal Symptoms in Infants

Gastrointestinal Symptoms in Young Infants

Switzerland
University of Zurich
University of Basel

Recruiting

Oxytocin Administration Prior Planned Caesarean Section

Respiratory Insufficiency Syndrome of Newborn | Breastfeeding Status

Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
University Hospital Inselspital, Berne

Recruiting

Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions (CBI-Registry)

Silent Cerebral Infarct | Silent Stroke | Silent Brain Infarction | Covert Brain Infarct | Covert Brain Infarction | Lacune

Switzerland, France
University Hospital Inselspital, Berne

Completed

Parental Involvement in Pain Reducing Measures

Preterm Infants | Parents | Procedural Pain

Switzerland
Pfizer

Completed

Genotropin Treatment In Very Young Children Born Small For Gestational Age (EGN)

Infant, Small for Gestational Age

Czech Republic, Spain, Sweden, Netherlands, Belgium, France, Germany, Italy, Switzerland
Swiss Federal Institute of Technology
North-West University, South Africa

Completed

Establishing the Iodine Requirement in Infancy

Focus: Establish the Iodine Requirement During Infancy

Switzerland, South Africa
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Bambino Gesù Hospital and Research Institute
Radboud University Medical Center; University of Exeter; Consorzio per Valutazioni...

Recruiting

A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection (cASPerCF)

Cystic Fibrosis | Aspergillosis

Ireland, Spain, Netherlands, France, United Kingdom, Czechia, Germany, Greece, Italy, Portugal, Switzerland
Novartis Pharmaceuticals

Completed

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years (EARLY)

Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Egypt, Greece, Hungary, Russian Federation, Canada, Germany, France, Italy, Switzerland, Romania
Alexion Pharmaceuticals

Completed

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

Lysosomal Acid Lipase Deficiency | Cholesterol Ester Storage Disease(CESD)

United States, United Kingdom, France, Canada, Czech Republic, Italy, Poland, Switzerland
University Hospital Tuebingen
Oslo University Hospital; University of Zurich; KU Leuven; UMC Utrecht; University... and other collaborators

Recruiting

Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO)

Infant, Newborn, Diseases | Encephalopathy, Hypoxic-Ischemic

Netherlands, Germany, Belgium, Austria, Estonia, Finland, Italy, Norway, Spain, Switzerland, Poland, Portugal
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Finland, Switzerland, Netherlands, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
Insel Gruppe AG, University Hospital Bern

Recruiting

Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions (SILENT2)

Silent Cerebral Infarct | Silent Stroke | Fibrillation

Switzerland, Germany, Austria
University Hospital Inselspital, Berne

Recruiting

Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)

Cerebral Amyloid Angiopathy | Cadasil | Small Vessel Cerebrovascular Disease | CAA - Cerebral Amyloid Angiopathy

Switzerland
Abbott Medical Devices

Recruiting

Trevisio Post-Approval Study (TrevisioPAS)

PFO - Patent Foramen Ovale | VSD - Muscular Ventricular Septal Defect | PIVSD - Post Infarct Muscular Ventricular Septal Defect | ASD - Atrial Septal Defect

Spain, Germany, Poland, France, Italy, Netherlands, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland

Clinical Trials on Newborn Infant in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations